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Introduction CYP2A13, a functional member of the human CYP2A gene subfamily, is selectively expressed in the respiratory tract (Koskela et al., 1999; Su et al., 2000; Zhu et al., 2006) , and is the most efficient P450 enzyme in the metabolic activation of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Su et al., 2000; He et al., 2004; Jalas et al., 2005) . CYP2A13 protein has been detected in human nasal mucosa and lung (Wong et al., 2005; Zhang et al., 2007) . In human lungs, levels of CYP2A13 protein expression were correlated with rates of lung microsomal NNK metabolic activation (Zhang et al., 2007) .
The CYP2A13*2 allele, which has a decreased level of gene expression, and encodes a variant CYP2A13 protein with reduced activity toward NNK (Zhang et al., 2002; D'Agostino et al., 2008) , is associated with a reduced risk of smoking-induced lung adenocarcinoma (Wang et al., 2003) . More recently, CYP2A13 was found to mediate NNK-induced lung tumorigenesis in a CYP2A13-humanized mouse model (Megaraj et al., 2014) . These findings strongly suggest that CYP2A13 plays an important role in the metabolic activation of NNK in the respiratory tract of human smokers.
A large interindividual variation in the detected levels of CYP2A13 expression (<2 to 20 fmol/mg microsomal protein) in human lung biopsy samples was previously reported (Zhang et al., 2007) . Given the potential impact of differences in lung CYP2A13 expression levels on the susceptibility to tobacco smoke-induced lung cancer, we have been searching for factors that dictate the apparently large interindividual variations in CYP2A13 expression. While some CYP2A13 genetic variants (e.g., *2 and 7520C>G) are associated with decreased allelic expression in human lung (Zhang et al., 2004; D'Agostino et al., 2008; Wu et al., 2009) , we also obtained evidence supporting the hypothesis that CYP2A13 levels in human lung can be suppressed by inflammation associated with disease status in tissue donors (Wu et al., 2013) . In DMD #63305
the latter study, we demonstrated that the bacterial endotoxin lipopolysaccharide (LPS) can suppress CYP2A13 expression in vitro, in the NCI-H441 human lung cell line, and in vivo, in a CYP2A13-humanized (CYP2A13-transgenic/Cyp2a5-null) mouse model, via a mechanism that involves regulatory sequences in the CYP2A13 promoter region and the nuclear factor NF-κB.
The human lung biopsy samples examined in our previous study were mainly resected, histologically normal lung tissues from patients with lung tumors (Zhang et al., 2007) . The aim of this study was to test the hypothesis that CYP2A13 levels in resected non-tumor lung tissues can be suppressed by the inflammation induced by the presence of lung tumors, in the CYP2A13-humanized mouse model. Lung tumors were induced in CYP2A13-humanized mice (on A/J background) by a single, intraperitoneal NNK injection. Tumor-bearing mice and control (saline-treated, tumor-free) mice were examined 16 weeks later for levels of CYP2A13 expression in lung tissues, and for signs of pulmonary or systemic inflammation. Our results provide further experimental proof to support the idea that the levels of CYP2A13 (and possibly other CYPs) detected in patient-derived lung tissues are lower than the levels present in normal, healthy human lung, a notion that has significant implications for efforts to delineate the roles of human lung P450 enzymes in xenobiotic metabolism, pulmonary pathogenesis, and chemical carcinogenesis.
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Materials and Methods
Animal treatments.
All procedures involving animals were approved by the Institutional Animal Care and Use Committee of the Wadsworth Center. The conditions and protocols for NNK lung tumor bioassay for the CYP2A13-humanized mouse model (CYP2A13/2B6/2F1-transgenic/Cyp2a5-null; A/J-N5) have been described (Megaraj et al., 2014) . Tissues from that project were used for this study. SuperScriptIII first-strand synthesis system (Invitrogen). Briefly, 2.5 µg of total lung RNA or 5 µg of total liver RNA was treated with DNase I (Invitrogen) at room temperature for 15 min, and then were mixed with standard amounts of oligo(dT) and other components of the system in final volume of 20 µl. Each reaction mixture was incubated at 50°C for 50 min. PCR reactions were carried out essentially as described (Zhang et al., 2007) . Levels of various mRNAs were normalized to those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers used were: GAPDH-F (5'-tgtgaacggatttggccgta-3') and GAPDH-R (5'-tcgctcctggaagatggtga-3') (Wei et al., 2012) ; mSAP-F (5'-tactgctttggatgtttgtcttcac-3') and mSAP-R (5'-tcagcttcacatgattttcag-3') (Charles et al., 2006) ; CYP2B10-F (5'-caggtgatcggctcacacc-3') and CYP2B10-R(5'-tgactgcatctgagtatggcatt-3'); CYP3A11-F (5'-ggatgagatcgatgaggctctg-3') and CYP3A11-R (5'-caggtattccatctccatcacagt-3') (Pan et al., 2000) ; CYP2F2-F1 (5'-aaagaagcatcgaggagc-3') and CYP2F2-R1 (5'-cgaagacgacagagcagat-3') (Braeuning et al., 2009) ; CYP2A13E6F (5'-acctggtgatgaccaccc-3') and CYP2A13E7R (5'-cgtggatcactgcctctg-3') (Zhang et al., 2004) .
Microsome preparation and immunoblot analysis. Microsome preparation and
immunoblot analysis were performed essentially as described previously (Ding and Coon, 1990) .
Microsomal proteins were separated on NuPAGE Bis-Tris Mini gels (10%) (Invitrogen). Rabbit antibodies against CYP2A5 (Gu et al., 1998) or calnexin (Genscript, Piscataway, NJ ) and a goat anti-rabbit secondary antibody (Sigma) were used.
Histopathological analysis of dissected adjacent lung tissues. Frozen lung tissues that
have been dissected to remove all visible tumors were thawed in saline at 4°C for 30 min, and then fixed in 4% PFA overnight, and embedded with paraffin. To search for interior tumors that were missed by the initial visual inspection, 10 serial sections covering each entire lung lobe were obtained and stained with H&E for histopathological analysis. The cross-sectional diameters of the adenoma lesions in each slide, measured by a stage micrometer transposed onto This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Repression of CYP2A13 expression in the lungs of NNK-treated, tumor-bearing mice
Four different NNK doses (30, 50, 100, and 200 mg/kg) were used in the original tumor bioassay (Megaraj et al., 2014) ; but tissues from only the two lower doses and the saline control group are analyzed here, as the lungs from the two high dose groups had too many tumors, which made it difficult to dissect adjacent "tumor-free" tissues. As reported in the original study (Megaraj et al., 2014) , essentially all NNK-treated CYP2A13-humanized mice had observable lung tumors at 16 weeks after the NNK treatment (tumor frequency: 100% and 95%; tumor multiplicity: 13.1 and 4.4 tumors per lung; for the 50 mg/kg and 30 mg/kg NNK dose groups, respectively). Approximately 9% of saline-treated CYP2A13-humanized mice also had lung tumor (each mouse had ~1 tumor per lung). Ten mice with lung tumors, from each of the two NNK-treated groups, were used for dissecting adjacent lung tissues; whereas three mice without lung tumors, from the saline treated group, were used as controls. The lung tumors were visible from the surface. The identification of lung tumors was confirmed by histopathological analysis (Megaraj et al., 2014) . The boundaries of the tumors, which distort the alveolar architecture, were usually well demarcated, allowing easy removal of the tumors during dissection.
The "tumor-free", adjacent lung tissues are defined as tissues without visible tumors. In a pilot study, we assessed the potential presence of smaller tumors, which were too small to be seen, by performing histological analysis of dissected lung tissues from four NNK-treated mice (one lung lube each). By examining serial sections through the entire lung lobes, we found 2-5 additional (small) tumorous lesions per lung lobe, from which visible tumors had been removed.
However, these small tumorous lesions were found to correspond to, on average, no more than ~2% (based on space occupied) to ~6% (based on the number of cells) of the lung lobes analyzed (Supplemental Table 1 ).
This article has not been copyedited and formatted. The final version may differ from this version. CYP2A13 protein expression was examined by immunoblot analysis in microsomes prepared from tumor-free lung tissues. CYP2A13 protein was detected in both NNK-treated groups and the saline control group (Fig. 1A) . As reported recently, the anti-CYP2A5 polyclonal antibody detects a non-specific band in the lungs of both Cyp2a5-null mice and the CYP2A13-humanized mice (Wei et al., 2013) . As expected, the CYP2A13 band was not detected in lung microsomes from the Cyp2a5-null mice, which served as a negative control. Compared to the saline treated group, the level of CYP2A13 protein was reduced significantly (by >60%) in both NNK-treated groups (Fig. 1B ).
CYP2A13 mRNA expression was also examined, in total RNA prepared from tumor-free lung tissues. Compared to the saline control group, CYP2A13 mRNA levels were decreased by ~50% in the 30 mg/kg group (though statistical significance was not reached) and by ~80% in the 50 mg/kg group (p < 0.01) (Fig. 1C) . Notably, there was no difference in CYP2A13 mRNA level between saline and NNK (30 or 50 mg/kg) groups at one week after dosing (Fig. 1D) , a result indicating that NNK injection per se did not suppress lung CYP2A13 expression.
The effects of lung tumorigenesis on the expression of mouse P450s were also examined.
The levels of murine CYP2B10 and CYP2F2 mRNAs were significantly lower (p < 0.05) in the dissected adjacent lung tissues from tumor-bearing mice, than in lungs from saline treated control mice (Supplemental Fig. 1A, 1B) . In contrast, the levels of hepatic CYP2B10 and CYP3A11 mRNAs in the tumor-bearing mice were similar to those in the control group (Supplemental Fig. 1C, 1D ). These results suggest that the lung tumorigenesis had a general, but tissue-specific effect on lung P450 expression.
Tumor-related inflammatory response in the NNK-treated, tumor-bearing mice
To evaluate whether systemic inflammation was induced in the tumor-bearing mice, we measured serum levels of three proinflammatory cytokines, IL-6, TNF-α and IFN-γ, by ELISA, This article has not been copyedited and formatted. The final version may differ from this version. (Wu et al., 2013) . However, none of the three proinflammatory cytokines was detected in the sera of either saline-treated or NNKtreated/tumor-bearing CYP2A13-humanized mice (data not shown; detection limits were: TNF-α and IFN-γ, ~30 pg/ml, IL-6, ~15 pg/ml); whereas hepatic SAP mRNA levels were very low and not significantly different between the control and tumor-bearing groups ( Fig. 2A) . These results indicated absence of a systemic inflammation in the tumor-bearing mice, at the time when tumors were counted (16 weeks after NNK treatment). In contrast, all three cytokines were detected, albeit at relatively low levels, in lung tissue homogenates and their levels were significantly higher (p < 0.05) in tumor-bearing mice than in control mice ( Fig. 2B-2D ). These data suggest occurrence of a low grade of lung inflammation in the tumor-bearing mice that were treated with NNK at 30 or 50 mg/kg for tumor induction. In other studies not presented, more sever lung inflammation was observed in tumor-bearing mice from the 200 mg/kg-NNK group, including tissue injury and mononuclear cell infiltration.
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DISCUSSION
We found no evidence of systemic inflammation in our mouse lung tumor model, at the time when tissues were collected for analysis of CYP2A13 expression. This finding was not surprising, as systemic inflammation usually occurs only in cases of advanced cancer (Martin et al., 1999) . On the other hand, local inflammation in the lungs of the tumor-bearing mice was evident, as shown by significant elevation in levels of IL-6, TNF-α, and IFN-γ in lung homogenates. Thus, it is highly likely that the suppression of CYP2A13 expression observed in the present lung tumor model was mediated through tumor-derived local inflammation in the lung. In that regard, we have already shown that systemic inflammation, induced by LPS treatment, can suppress lung CYP2A13 expression in the same CYP2A13-humanized mouse model (Wu et al., 2013) . Additionally, data in Figure 1D confirmed that a single-dose NNK injection per se would not repress CYP2A13 expression, prior to lung tumorigenesis.
The absence of systemic inflammation in our lung tumor model also explains the tissue specific suppression of CYP repression in the lung, but not in the liver, of NNK-treated, tumorbearing mice. Our results contrast with a previous report that tumor-bearing mice had reduced hepatic CYP levels and altered CYP enzyme activity. By using an explant sarcoma in a transgenic mouse model of human CYP3A4 regulation, Charles and co-workers (Charles et al., 2006) demonstrated an association between the reduction in CYP3A4 expression and occurrence of tumor-derived inflammation. However, in the xenograft model of solid tumors used, the tumor mass reached ~3 g or 10% of total body weight over 17 -21 days and acute-phase response was induced in the tumor-bearing mice. In contrast, the tumor-bearing mice in our study had normal weight gain (at the two doses examined) and the volume of tumor lesion was very small, which explains the lack of a systemic inflammation.
This article has not been copyedited and formatted. The final version may differ from this version. In this study, the dissected "tumor-free" lung tissues might have contained some additional tumors that were too small to be seen. Given that CYP2A13 is normally not expressed in human lung cancer cell lines (Ling et al., 2007) , we suspect that CYP2A13 expression within the tumor cells was also suppressed. This reduction would contribute to the overall decrease in CYP2A13 levels detected in the dissected "tumor-free" lung tissues from the tumor-bearing mice.
Nonetheless, we estimated that the total number of tumor cells in the dissected lungs of NNKtreated mice was on average only no more than 6% of the total cells, an abundance that would not explain the more than 50% decreases in overall CYP2A13 expression level that was actually observed. Thus, we conclude that the observed decreases in CYP2A13 levels in the lungs of NNK-treated, tumor-bearing mice mainly reflect suppression of CYP2A13 expression in adjacent, histologically normal lung tissues, rather than a possible loss of CYP2A13 expression in the tumor itself.
In summary, by studying a CYP2A13-humanized mouse model, we have demonstrated for the first time that the expression of human CYP2A13 transgene was repressed in the presence of lung tumors. Accompanying the decrease in CYP2A13 expression, three proinflammatory cytokines (IL-6, TNF-α, and IFN-γ) were up-regulated in the lungs of tumor-bearing mice. These findings further support our hypothesis (Wu et al., 2013) that the low expression of CYP2A13 observed in the resected, histologically normal lung biopsy tissues from patients with lung cancers (Zhang et al., 2007) was caused at least in part by the tumor-induced chronic inflammation in the lung. In that regard, most studies on gene expression in human lungs use tissue samples that were available from patients suffering from lung diseases or from organ donors who had been subjected to surgical conditions that could induce lung inflammation. The results of these studies are commonly taken to represent tissue levels of gene expression in people (healthy or not). However, our findings imply that, for CYP2A13, the detected levels in available human lung tissue samples are much lower than the levels in healthy, intact human lungs.
